Potential theranostic approach of 177Lu-trastuzumab and 177Lu-FAPI in metastatic breast cancer: An ongoing study

被引：0
|
作者：
Assadi, M. [1 ]
Rekabpour, S. [1 ]
Jokar, N. [1 ]
Ahmadzadehfar, H. [2 ]
Jafari, E. [1 ]
机构：
[1] Bushehr Univ Med Sci BUMS, Bushehr, Iran
[2] Klinikum Westfalen, Dept Nucl Med, Dortmund, Germany
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2021年 / 48卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
OP-0815
引用
收藏
页码：S291 / S291
页数：1
相关论文
共 50 条
  • [31] NEW HOPE FOR METASTATIC PROSTATE CANCER TREATMENT: LU-177 PSMA
    James, D.
    Alchin, S.
    Batley, S.
    Muchirahondo, C.
    Sharp, C.
    Sipowicz, S.
    Watson, T.
    INTERNAL MEDICINE JOURNAL, 2016, 46 : 31 - 31
  • [32] Outcome and safety of rechallenge [177Lu]Lu-PSMA-617 in patients with metastatic prostate cancer
    Yordanova, Anna
    Linden, Paula
    Hauser, Stefan
    Meisenheimer, Michael
    Kuerpig, Stefan
    Feldmann, Georg
    Gaertner, Florian C.
    Essler, Markus
    Ahmadzadehfar, Hojjat
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2019, 46 (05) : 1073 - 1080
  • [33] Outcome and safety of rechallenge [177Lu]Lu-PSMA-617 in patients with metastatic prostate cancer
    Anna Yordanova
    Paula Linden
    Stefan Hauser
    Michael Meisenheimer
    Stefan Kürpig
    Georg Feldmann
    Florian C. Gaertner
    Markus Essler
    Hojjat Ahmadzadehfar
    European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46 : 1073 - 1080
  • [34] Matched-pair analysis of [177Lu]Lu-PSMA I&T and [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer
    Philipp E. Hartrampf
    Franz-Xaver Weinzierl
    Andreas K. Buck
    Steven P. Rowe
    Takahiro Higuchi
    Anna Katharina Seitz
    Hubert Kübler
    Andreas Schirbel
    Markus Essler
    Ralph A. Bundschuh
    Rudolf A. Werner
    European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49 : 3269 - 3276
  • [35] Matched-pair analysis of [177Lu]Lu-PSMA I&T and [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer
    Hartrampf, Philipp E.
    Weinzierl, Franz-Xaver
    Buck, Andreas K.
    Rowe, Steven P.
    Higuchi, Takahiro
    Seitz, Anna Katharina
    Kuebler, Hubert
    Schirbel, Andreas
    Essler, Markus
    Bundschuh, Ralph A.
    Werner, Rudolf A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022, 49 (09) : 3269 - 3276
  • [36] Theranostic role of89Zr/177Lu-labeled aflibercept in triple-negative breast cancer
    Kang, L.
    Yang, Q.
    Chen, Z.
    Qiu, Y.
    Huang, W.
    Song, L.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2023, 50 (SUPPL 1) : S282 - S283
  • [37] Theranostic probe Lu-177-DOTA-NIR790 for multimodal diagnosis and therapy of cancer
    Peng, C.
    Shih, Y.
    Chiang, P.
    Kuo, Y.
    Luo, T.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 : S543 - S543
  • [38] Preclinical evaluation of novel theranostic heterodimeric ligands [68Ga]Ga/[177Lu]Lu-DOTA-FAPI-BPsfor tumor bone metastasis
    Deng, Y.
    Jin, W.
    Zhang, Z.
    Wang, X.
    Zhao, R.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 : S450 - S450
  • [39] The value of tumor markers in men with metastatic prostate cancer undergoing [177Lu]Lu-PSMA therapy
    Yordanova, Anna
    Linden, Paula
    Hauser, Stefan
    Feldmann, Georg
    Brossart, Peter
    Fimmers, Rolf
    Essler, Markus
    Holdenrieder, Stefan
    Ahmadzadehfar, Hojjat
    PROSTATE, 2020, 80 (01): : 17 - 27
  • [40] Treatment of Bone Metastases of Breast Cancer With 177Lu-DOTA-IBA
    Deng, Jia
    Yang, Jian
    Cheng, Zixuan
    Chen, Yue
    CLINICAL NUCLEAR MEDICINE, 2024, 49 (07) : 659 - 661
12345